Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Mathias Due BuronThor Ameri ChalmerFinn SellebjergIsmael BarzinjiJeppe Romme ChristensenMette Kirstine ChristensenVictoria HansenZsolt IllesHenrik Boye JensenMatthias KantViktoria PappThor PetersenPeter Vestergaard RasmussenJakob SchäferÁsta TheódórsdóttirArkadiusz WeglewskiPer Soelberg SorensenMelinda MagyariPublished in: Neurology (2020)
This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.